Novo Nordisk Expands Wegovy® Access via Telehealth
Slice of Healthcare Team
Apr 30, 2025
Key Highlights
- Novo Nordisk partners with Hims & Hers, LifeMD, and Rofor streamlined Wegovy® access through telehealth.
- Wegovy® now available at $499/monthfor self-paying patients, including via local pharmacies.
- NovoCare® Pharmacy enables direct home deliverywith full-dose availability and support services.
- FDA-approved semaglutide now indicated for cardiovascular risk reductionin obese patients with heart disease.
Source: PR Newswire
Notable Quote
“ Wegovy® continues to be in high demand... Making Wegovy® available via these telehealth channels... is an important step forward in allowing patients to receive care in the way they choose. ”
Dave Moore, EVP, U.S. Operations and President at Novo Nordisk Inc
Why This Matters
This move by Novo Nordisk marks a pivotal advancement in the fight against obesity by significantly enhancing patient access to clinically-proven weight loss treatments. As demand for Wegovy® grows and telehealth becomes a preferred healthcare model, integrating top digital health providers with NovoCare® Pharmacy bridges a crucial gap—offering convenience, affordability, and authenticity. By reducing barriers to entry, Novo Nordisk is reinforcing its leadership in obesity care and expanding the reach of its life-changing therapy to more than 100 million Americans affected by this chronic condition.
